Nicholas J. Bergo

This paper demonstrates that a synNotch receptor can target extracellular Aβ aggregates, enabling the production of AD therapies like Lecanemab and Aducanumab in response to these aggregates.

The paper evaluates senolytic therapies in a human neuron AD model, finding Navitoclax's neurotoxicity and NK92's preferential targeting of senescent-like cells.

The paper demonstrates that CARs based on AD antibodies can detect and discriminate between tau and distinct Aβ species, suggesting their potential for targeted AD therapies.